Literature DB >> 23671078

Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment.

Emilyne Blattes1, Alain Vercellone, Hélène Eutamène, Cédric-Olivier Turrin, Vassilia Théodorou, Jean-Pierre Majoral, Anne-Marie Caminade, Jacques Prandi, Jérôme Nigou, Germain Puzo.   

Abstract

Mycobacterium tuberculosis mannose-capped lipoarabinomannan inhibits the release of proinflammatory cytokines by LPS-stimulated human dendritic cells (DCs) via targeting the C-type lectin receptor DC-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN). With the aim of mimicking the bioactive supramolecular structure of mannose-capped lipoarabinomannan, we designed and synthesized a set of poly(phosphorhydrazone) dendrimers grafted with mannose units, called mannodendrimers, that differed by size and the number and length of their (α1→2)-oligommanoside caps. A third-generation dendrimer bearing 48 trimannoside caps (3T) and a fourth-generation dendrimer bearing 96 dimannosides (4D) displayed the highest binding avidity for DC-SIGN. Moreover, these dendrimers inhibited proinflammatory cytokines, including TNF-α, production by LPS-stimulated DCs in a DC-SIGN-dependent fashion. Finally, in a model of acute lung inflammation in which mice were exposed to aerosolized LPS, per os administration of 3T mannodendrimer was found to significantly reduce neutrophil influx via targeting the DC-SIGN murine homolog SIGN-related 1. The 3T mannodendrimer therefore represents an innovative fully synthetic compound for the treatment of lung inflammatory diseases.

Entities:  

Keywords:  ManLAM functional analogs; SIGNR1 targeting; antiinflammatory molecule; glycodendrimer synthesis; multivalent ligands

Mesh:

Substances:

Year:  2013        PMID: 23671078      PMCID: PMC3670345          DOI: 10.1073/pnas.1221708110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Synthesis and biological properties of mannosylated starburst poly(amidoamine) dendrimers.

Authors:  D Pagé; R Roy
Journal:  Bioconjug Chem       Date:  1997 Sep-Oct       Impact factor: 4.774

2.  Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers.

Authors:  Laurent Griffe; Mary Poupot; Patrice Marchand; Alexandrine Maraval; Cédric-Olivier Turrin; Olivier Rolland; Pascal Métivier; Gérard Bacquet; Jean-Jacques Fournié; Anne-Marie Caminade; Rémy Poupot; Jean-Pierre Majoral
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

3.  DC-SIGN neck domain is a pH-sensor controlling oligomerization: SAXS and hydrodynamic studies of extracellular domain.

Authors:  Georges Tabarani; Michel Thépaut; David Stroebel; Christine Ebel; Corinne Vivès; Patrice Vachette; Dominique Durand; Franck Fieschi
Journal:  J Biol Chem       Date:  2009-06-05       Impact factor: 5.157

4.  Synthesis and immunoreactivity of neoglycoproteins containing the trisaccharide unit of phenolic glycolipid I of Mycobacterium leprae.

Authors:  D Chatterjee; S N Cho; C Stewart; J T Douglas; T Fujiwara; P J Brennan
Journal:  Carbohydr Res       Date:  1988-12-01       Impact factor: 2.104

5.  Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor.

Authors:  J Nigou; C Zelle-Rieser; M Gilleron; M Thurnher; G Puzo
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands.

Authors:  D A Mitchell; A J Fadden; K Drickamer
Journal:  J Biol Chem       Date:  2001-05-30       Impact factor: 5.157

7.  Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages.

Authors:  L S Schlesinger; S R Hull; T M Kaufman
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

8.  Tailored control and optimisation of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes.

Authors:  Olivier Rolland; Laurent Griffe; Mary Poupot; Alexandrine Maraval; Armelle Ouali; Yannick Coppel; Jean-Jacques Fournié; Gérard Bacquet; Cédric-Olivier Turrin; Anne-Marie Caminade; Jean-Pierre Majoral; Rémy Poupot
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

9.  Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells.

Authors:  Alessandra Cambi; Frank de Lange; Noortje M van Maarseveen; Monique Nijhuis; Ben Joosten; Erik M H P van Dijk; Bärbel I de Bakker; Jack A M Fransen; Petra H M Bovee-Geurts; Frank N van Leeuwen; Niek F Van Hulst; Carl G Figdor
Journal:  J Cell Biol       Date:  2004-01-05       Impact factor: 10.539

10.  Mycobacteria target DC-SIGN to suppress dendritic cell function.

Authors:  Teunis B H Geijtenbeek; Sandra J Van Vliet; Estella A Koppel; Marta Sanchez-Hernandez; Christine M J E Vandenbroucke-Grauls; Ben Appelmelk; Yvette Van Kooyk
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more
  19 in total

1.  Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.

Authors:  Keerti Jain; Ashwni Kumar Verma; Prabhat Ranjan Mishra; Narendra Kumar Jain
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Neutral high-generation phosphorus dendrimers inhibit macrophage-mediated inflammatory response in vitro and in vivo.

Authors:  I Posadas; L Romero-Castillo; N El Brahmi; D Manzanares; S Mignani; J-P Majoral; V Ceña
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

Review 3.  Cell membrane-derived nanomaterials for biomedical applications.

Authors:  Ronnie H Fang; Yao Jiang; Jean C Fang; Liangfang Zhang
Journal:  Biomaterials       Date:  2017-03-01       Impact factor: 12.479

4.  Covalent modifications of polysaccharides in mycobacteria.

Authors:  Shiva K Angala; Zuzana Palčeková; Juan M Belardinelli; Mary Jackson
Journal:  Nat Chem Biol       Date:  2018-02-14       Impact factor: 15.040

5.  In vivo proinflammatory activity of generations 0-3 (G0-G3) polyamidoamine (PAMAM) nanoparticles.

Authors:  Isabelle Durocher; Denis Girard
Journal:  Inflamm Res       Date:  2016-06-23       Impact factor: 4.575

Review 6.  The cell envelope glycoconjugates of Mycobacterium tuberculosis.

Authors:  Shiva Kumar Angala; Juan Manuel Belardinelli; Emilie Huc-Claustre; William H Wheat; Mary Jackson
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-06-10       Impact factor: 8.250

Review 7.  Manipulation of the endocytic pathway and phagocyte functions by Mycobacterium tuberculosis lipoarabinomannan.

Authors:  Isabelle Vergne; Martine Gilleron; Jérôme Nigou
Journal:  Front Cell Infect Microbiol       Date:  2015-01-12       Impact factor: 5.293

8.  IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals.

Authors:  Fekadu Abebe; Mulugeta Belay; Mengistu Legesse; Franken K L M C; Tom H M Ottenhoff
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

Review 9.  Pro-Inflammatory Versus Anti-Inflammatory Effects of Dendrimers: The Two Faces of Immuno-Modulatory Nanoparticles.

Authors:  Séverine Fruchon; Rémy Poupot
Journal:  Nanomaterials (Basel)       Date:  2017-09-01       Impact factor: 5.076

10.  Deciphering the molecular basis of mycobacteria and lipoglycan recognition by the C-type lectin Dectin-2.

Authors:  Alexiane Decout; Sandro Silva-Gomes; Daniel Drocourt; Emilyne Blattes; Michel Rivière; Jacques Prandi; Gérald Larrouy-Maumus; Anne-Marie Caminade; Beston Hamasur; Gunilla Källenius; Devinder Kaur; Karen M Dobos; Megan Lucas; Iain C Sutcliffe; Gurdyal S Besra; Ben J Appelmelk; Martine Gilleron; Mary Jackson; Alain Vercellone; Gérard Tiraby; Jérôme Nigou
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.